The FY2026 20-F confirms a deteriorating fundamental picture: widening losses, accelerating cash burn, and relentless dilution via the White Lion ELOC. The PsyLabs equity stake provides no near-term revenue. Watch for the next Phase IIb data readout and any further ELOC draws, which will continue to pressure the stock. The $7.49M cash balance provides a limited runway given the $8.14M annual operating burn.
Price Chart
Executive Summary
Psyence Biomedical filed its annual 20-F for FY2026, reporting a net loss of $6.89 million (vs. $1 million profit in FY2025, which was driven by non-cash fair value gains). The company remains pre-revenue with no approved products. R&D spend surged to $1.47 million (up from $0.34 million) as the Phase IIb trial accelerated. Cash stood at $7.49 million, but the company continues to rely on its dilutive $100M White Lion equity line (drew $14.5M in FY2026 and $16.9M post-year-end). The 27.93% equity-method stake in PsyLabs (carrying value $8.06M) is now a material non-cash asset. A $1.5M settlement with activist KAOS Group was a one-time drag. The filing is bearish: widening losses, accelerating cash burn, heavy equity dilution, and no near-term revenue catalyst.
Key Facts
- Net loss of $6.89 million for FY2026 vs. $1.01 million profit in FY2025 (prior year profit driven by non-cash fair value gains).
- No revenue generated; no products approved for commercial sale.
- R&D expenses increased to $1.47 million from $0.34 million YoY, reflecting Phase IIb trial acceleration.
- Cash and restricted cash of $7.49 million as of March 31, 2026.
- Issued 1,051,973 shares under the White Lion ELOC for gross proceeds of $14.55 million in FY2026; post-year-end issued another 1,517,163 shares for $16.92 million.
- Equity-method investment in PsyLabs (27.93% stake) carried at $8.06 million; recognized $45,239 share of PsyLabs net loss.
- Settled KAOS Group shareholder dispute for $1.5 million cash in February 2026.
- Outstanding shares ballooned to 2,293,277 as of March 31, 2026, from 90,883 a year earlier — a 25x increase.
- Warrant overhang: 45,112 shares issuable upon exercise of various warrants, mostly deeply out-of-the-money.
- Management concluded disclosure controls and internal control over financial reporting were effective.
Financial Impact
Net loss widened by $7.9 million YoY to $6.89 million. Operating cash burn was $8.14 million. Dilution from ELOC draws: 1.05M shares in FY2026 and 1.52M post-year-end.
Risk Factors
- Continued dilution from the $100M White Lion equity line; post-year-end draws already add 66% to the share count.
- No approved products or revenue; clinical-stage risk for NPX-5 Phase IIb trial.
- Nasdaq continued listing risk given history of non-compliance and low market cap ($7M).
- Dependence on PsyLabs for drug supply and IP; PsyLabs is a development-stage associate with losses.
- Potential PFIC classification for U.S. holders, with adverse tax consequences.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001213900-26-070607 |
| Document: ea029498301ex12-2.htm | 0001213900-26-070607 |
| Document: ea029498301ex12-1.htm | 0001213900-26-070607 |
| Document: ea029498301ex13-1.htm | 0001213900-26-070607 |
| Document: ea029498301ex23-1.htm | 0001213900-26-070607 |
| Document: 0001213900-26-070607-index-headers.html | 0001213900-26-070607 |
| Document: 0001213900-26-070607-index.html | 0001213900-26-070607 |
| Document: 0001213900-26-070607.txt | 0001213900-26-070607 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $4.52 $4.12 | ▼ −8.85% | ▼ −7.67% | $3.66 (−19.03%) |
Oct 15, 2026 11d ago | SC 13D/A | $4.32 $4.22 | ▼ −2.31% | ▼ −1.21% | $3.66 (−15.28%) |
Oct 5, 2026 21d ago | SC 13G | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | 6-K | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Oct 5, 2026 21d ago | Press Release | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $3.66 (−27.95%) |
Sep 28, 2026 28d ago | 6-K | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 28, 2026 28d ago | Press Release | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $3.66 (−35.39%) |
Sep 23, 2026 4w ago | 6-K | $6.31 $5.86 | ▲ +7.13% | ▲ +7.05% | $3.66 (+42.00%) |
Sep 14, 2026 6w ago | 6-K | $6.00 $6.07 | ▲ +1.17% | ▲ +1.63% | $3.66 (−39.00%) |
Sep 2, 2026 7w ago | EFFECT | $4.37 $4.43 | ▲ +1.37% | ▲ +0.33% | $3.66 (−16.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers